Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Elliott Marshall Antman, M.D.

Co-Author

This page shows the publications co-authored by Elliott Antman and Eugene Braunwald.
Connection Strength

16.359
  1. The path to universality. Eur J Heart Fail. 2021 03; 23(3):381-383.
    View in: PubMed
    Score: 0.950
  2. Invasive or Conservative Strategy for Stable Coronary Disease. Reply. N Engl J Med. 2020 Sep 03; 383(10):e66.
    View in: PubMed
    Score: 0.917
  3. Managing Stable Ischemic Heart Disease. N Engl J Med. 2020 04 09; 382(15):1468-1470.
    View in: PubMed
    Score: 0.890
  4. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008 May 27; 51(21):2028-33.
    View in: PubMed
    Score: 0.392
  5. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Am Heart J. 2002 Feb; 143(2):229-34.
    View in: PubMed
    Score: 0.253
  6. A second look at bivalirudin. Am Heart J. 2001 Dec; 142(6):929-31.
    View in: PubMed
    Score: 0.250
  7. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J. 2000 Dec; 21(23):1944-53.
    View in: PubMed
    Score: 0.233
  8. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000 Aug 16; 284(7):835-42.
    View in: PubMed
    Score: 0.228
  9. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999 Oct 12; 100(15):1593-601.
    View in: PubMed
    Score: 0.215
  10. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999 Oct 12; 100(15):1602-8.
    View in: PubMed
    Score: 0.215
  11. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 1999 Jun 01; 99(21):2720-32.
    View in: PubMed
    Score: 0.210
  12. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy. J Am Coll Cardiol. 1998 Feb; 31(2):326-30.
    View in: PubMed
    Score: 0.192
  13. Evidence-based coronary care. Ann Intern Med. 1997 Apr 01; 126(7):551-3.
    View in: PubMed
    Score: 0.181
  14. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J. 2017 Mar 21; 38(12):888-896.
    View in: PubMed
    Score: 0.180
  15. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996 Oct 31; 335(18):1342-9.
    View in: PubMed
    Score: 0.176
  16. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016 Jul 05; 134(1):24-36.
    View in: PubMed
    Score: 0.172
  17. Trials and tribulations of thrombin inhibition. Eur Heart J. 1996 Jul; 17(7):971-3.
    View in: PubMed
    Score: 0.172
  18. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail. 2016 09; 18(9):1153-61.
    View in: PubMed
    Score: 0.171
  19. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016 05 20; 5(5).
    View in: PubMed
    Score: 0.170
  20. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. Am J Med. 2016 Aug; 129(8):850-857.e2.
    View in: PubMed
    Score: 0.168
  21. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc. 2016 Feb 23; 5(2).
    View in: PubMed
    Score: 0.167
  22. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. Am Heart J. 2016 Feb; 172:144-51.
    View in: PubMed
    Score: 0.165
  23. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 06; 385(9984):2288-95.
    View in: PubMed
    Score: 0.157
  24. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†. Eur Heart J. 2015 Jun 14; 36(23):1470-7.
    View in: PubMed
    Score: 0.156
  25. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2014 Aug 12; 64(6):576-84.
    View in: PubMed
    Score: 0.151
  26. New oral anticoagulants in patients with atrial fibrillation - Authors'reply. Lancet. 2014 Jul 05; 384(9937):25-6.
    View in: PubMed
    Score: 0.149
  27. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15; 383(9921):955-62.
    View in: PubMed
    Score: 0.144
  28. Dynamic TIMI risk score for STEMI. J Am Heart Assoc. 2013 Jan 29; 2(1):e003269.
    View in: PubMed
    Score: 0.135
  29. Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6.
    View in: PubMed
    Score: 0.133
  30. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol. 2011 Oct 01; 108(7):905-11.
    View in: PubMed
    Score: 0.122
  31. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011 Aug; 106(2):219-26.
    View in: PubMed
    Score: 0.121
  32. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011 Jun 14; 123(23):2681-9.
    View in: PubMed
    Score: 0.120
  33. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010 Oct; 160(4):635-41.
    View in: PubMed
    Score: 0.115
  34. Prasugrel. Circulation. 2010 Jul 27; 122(4):394-403.
    View in: PubMed
    Score: 0.114
  35. Mortality in the TRITON trial: update from the FDA prasugrel action package. Am J Cardiol. 2010 Jul 15; 106(2):293-4.
    View in: PubMed
    Score: 0.113
  36. Acute MI management in the 1990s. Hosp Pract (Off Ed). 1990 Jul 15; 25(7):65-75, 79-82.
    View in: PubMed
    Score: 0.113
  37. Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Eur Heart J. 2010 Sep; 31(17):2103-10.
    View in: PubMed
    Score: 0.112
  38. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2009 Sep 05; 374(9692):787-95.
    View in: PubMed
    Score: 0.107
  39. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. 2009 Jun 02; 119(21):2758-64.
    View in: PubMed
    Score: 0.105
  40. Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction. Am Heart J. 2009 Mar; 157(3):517-24.
    View in: PubMed
    Score: 0.103
  41. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 2007 Sep; 28(17):2077-86.
    View in: PubMed
    Score: 0.092
  42. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. Eur Heart J. 2007 Sep; 28(17):2070-6.
    View in: PubMed
    Score: 0.092
  43. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007 Jun 12; 49(23):2249-55.
    View in: PubMed
    Score: 0.091
  44. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation. 2007 Jun 05; 115(22):2822-8.
    View in: PubMed
    Score: 0.091
  45. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart J. 2007 May; 28(9):1066-71.
    View in: PubMed
    Score: 0.091
  46. Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). J Thromb Thrombolysis. 2006 Apr; 21(2):119-29.
    View in: PubMed
    Score: 0.084
  47. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006 Apr 06; 354(14):1477-88.
    View in: PubMed
    Score: 0.084
  48. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. Am Heart J. 2006 Feb; 151(2):360-6.
    View in: PubMed
    Score: 0.083
  49. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J. 2005 Feb; 149(2):217-26.
    View in: PubMed
    Score: 0.078
  50. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. Eur Heart J. 2005 Mar; 26(5):440-6.
    View in: PubMed
    Score: 0.078
  51. Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. Eur Heart J. 2004 Oct; 25(19):1702-10.
    View in: PubMed
    Score: 0.076
  52. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):783-9.
    View in: PubMed
    Score: 0.075
  53. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am Heart J. 2004 Aug; 148(2):336-40.
    View in: PubMed
    Score: 0.075
  54. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004 Jul 21; 44(2):335-9.
    View in: PubMed
    Score: 0.075
  55. The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. Eur Heart J. 2004 Jul; 25(13):1139-45.
    View in: PubMed
    Score: 0.075
  56. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol. 2004 Jun 01; 93(11):1362-7, A5-6.
    View in: PubMed
    Score: 0.074
  57. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004 Feb 10; 109(5):580-6.
    View in: PubMed
    Score: 0.073
  58. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004 Feb 24; 109(7):874-80.
    View in: PubMed
    Score: 0.073
  59. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003 Feb 11; 107(5):690-5.
    View in: PubMed
    Score: 0.068
  60. Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration. Am Heart J. 2002 Nov; 144(5):790-5.
    View in: PubMed
    Score: 0.067
  61. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002 Oct 02; 40(7):1366-74.
    View in: PubMed
    Score: 0.066
  62. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002 Oct 01; 106(14):1893-900.
    View in: PubMed
    Score: 0.066
  63. Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol. 2002 Aug 01; 90(3):303-5.
    View in: PubMed
    Score: 0.065
  64. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. J Am Coll Cardiol. 2002 Jul 17; 40(2):238-44.
    View in: PubMed
    Score: 0.065
  65. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J Am Coll Cardiol. 2002 Jul 03; 40(1):71-7.
    View in: PubMed
    Score: 0.065
  66. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. Eur Heart J. 2002 Jun; 23(12):928-33.
    View in: PubMed
    Score: 0.065
  67. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J. 2002 Jun; 143(6):966-70.
    View in: PubMed
    Score: 0.065
  68. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002 Apr 16; 105(15):1760-3.
    View in: PubMed
    Score: 0.064
  69. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation. 2002 Apr 09; 105(14):1642-9.
    View in: PubMed
    Score: 0.064
  70. Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. Crit Pathw Cardiol. 2002 Mar; 1(1):44-52.
    View in: PubMed
    Score: 0.064
  71. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002 Feb 15; 89(4):463-5.
    View in: PubMed
    Score: 0.063
  72. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002 Feb; 23(3):223-9.
    View in: PubMed
    Score: 0.063
  73. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J. 2002 Feb; 23(4):308-14.
    View in: PubMed
    Score: 0.063
  74. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet. 2001 Nov 10; 358(9293):1571-5.
    View in: PubMed
    Score: 0.062
  75. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001 Sep 19; 286(11):1356-9.
    View in: PubMed
    Score: 0.062
  76. A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48. J Am Coll Cardiol. 2021 Aug 10; 78(6):634-636.
    View in: PubMed
    Score: 0.061
  77. Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? J Am Coll Cardiol. 2021 Jun 29; 77(25):3232-3233.
    View in: PubMed
    Score: 0.061
  78. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2021 05 01; 42(17):1698-1706.
    View in: PubMed
    Score: 0.060
  79. A simple, readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction. Am J Cardiol. 2001 Apr 15; 87(8):1008-10; A5.
    View in: PubMed
    Score: 0.060
  80. Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021 Apr 09; 7(FI1):f40-f49.
    View in: PubMed
    Score: 0.060
  81. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. J Am Coll Cardiol. 2021 03 09; 77(9):1197-1207.
    View in: PubMed
    Score: 0.059
  82. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 Feb 16; 143(7):685-695.
    View in: PubMed
    Score: 0.059
  83. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Circulation. 2021 Feb 16; 143(7):673-684.
    View in: PubMed
    Score: 0.059
  84. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. J Clin Neurosci. 2021 Apr; 86:294-300.
    View in: PubMed
    Score: 0.059
  85. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Ann Intern Med. 1980 Dec; 93(6):875-85.
    View in: PubMed
    Score: 0.058
  86. Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II. Am J Cardiol. 2000 Dec 01; 86(11):1235-7, A5.
    View in: PubMed
    Score: 0.058
  87. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol. 2000 Nov 15; 36(6):1812-7.
    View in: PubMed
    Score: 0.058
  88. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 Feb 02; 143(5):470-478.
    View in: PubMed
    Score: 0.058
  89. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. Circ Cardiovasc Qual Outcomes. 2020 11; 13(11):e006511.
    View in: PubMed
    Score: 0.058
  90. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000 Oct 24; 102(17):2031-7.
    View in: PubMed
    Score: 0.058
  91. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thromb Haemost. 2021 Feb; 121(2):140-149.
    View in: PubMed
    Score: 0.057
  92. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation. 2000 Sep 05; 102(10):1193-209.
    View in: PubMed
    Score: 0.057
  93. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000 Sep; 36(3):970-1062.
    View in: PubMed
    Score: 0.057
  94. Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. Am Heart J. 2000 Sep; 140(3):373-8.
    View in: PubMed
    Score: 0.057
  95. Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med. 1980 Jun 05; 302(23):1269-73.
    View in: PubMed
    Score: 0.056
  96. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2020 03 17; 75(10):1095-1106.
    View in: PubMed
    Score: 0.055
  97. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol. 2000 Feb; 35(2):358-62.
    View in: PubMed
    Score: 0.055
  98. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. Am J Cardiol. 2000 Feb 01; 85(3):299-304.
    View in: PubMed
    Score: 0.055
  99. Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2020 04 01; 304:185-191.
    View in: PubMed
    Score: 0.055
  100. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation. 2000 Jan 25; 101(3):239-43.
    View in: PubMed
    Score: 0.055
  101. Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 12 17; 74(24):3013-3022.
    View in: PubMed
    Score: 0.054
  102. Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. Eur J Heart Fail. 2019 12; 21(12):1571-1579.
    View in: PubMed
    Score: 0.054
  103. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Nov 01; 34(5):1403-12.
    View in: PubMed
    Score: 0.054
  104. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation. 2019 11 26; 140(22):1792-1801.
    View in: PubMed
    Score: 0.054
  105. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1999 Oct; 34(4):974-82.
    View in: PubMed
    Score: 0.054
  106. Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B. J Am Coll Cardiol. 1999 Sep; 34(3):739-47.
    View in: PubMed
    Score: 0.053
  107. Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. Hypertension. 2019 09; 74(3):597-605.
    View in: PubMed
    Score: 0.053
  108. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. J Am Coll Cardiol. 2019 07 16; 74(2):179-189.
    View in: PubMed
    Score: 0.053
  109. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019 05 14; 40(19):1518-1527.
    View in: PubMed
    Score: 0.052
  110. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019 05 14; 40(19):1541-1550.
    View in: PubMed
    Score: 0.052
  111. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019 02 05; 139(6):760-771.
    View in: PubMed
    Score: 0.051
  112. Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. Europace. 2019 Feb 01; 21(2):306-312.
    View in: PubMed
    Score: 0.051
  113. Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 11 07; 39(42):3810-3820.
    View in: PubMed
    Score: 0.050
  114. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. Circulation. 2018 10 30; 138(18):1963-1973.
    View in: PubMed
    Score: 0.050
  115. Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol. 2018 09 25; 72(13):1466-1475.
    View in: PubMed
    Score: 0.050
  116. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial. J Am Heart Assoc. 2018 08 21; 7(16):e008987.
    View in: PubMed
    Score: 0.050
  117. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. Eur Heart J Acute Cardiovasc Care. 2019 Mar; 8(2):176-185.
    View in: PubMed
    Score: 0.049
  118. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998 Jun; 31(7):1460-5.
    View in: PubMed
    Score: 0.049
  119. Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. Thromb Haemost. 2018 06; 118(6):1001-1008.
    View in: PubMed
    Score: 0.049
  120. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e003998.
    View in: PubMed
    Score: 0.049
  121. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation. 1998 Mar 24; 97(11):1042-5.
    View in: PubMed
    Score: 0.048
  122. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol. 1998 Mar 15; 81(6):678-81.
    View in: PubMed
    Score: 0.048
  123. Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2018 04 15; 257:102-107.
    View in: PubMed
    Score: 0.048
  124. Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A. Am Heart J. 1997 Oct; 134(4):622-30.
    View in: PubMed
    Score: 0.047
  125. Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2017 Jun 30; 6(7).
    View in: PubMed
    Score: 0.046
  126. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol. 2017 Mar 21; 69(11):1372-1382.
    View in: PubMed
    Score: 0.045
  127. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circ Arrhythm Electrophysiol. 2017 01; 10(1).
    View in: PubMed
    Score: 0.044
  128. Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol. 2016 Dec 01; 1(9):999-1006.
    View in: PubMed
    Score: 0.044
  129. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. J Am Coll Cardiol. 2016 09 13; 68(11):1169-1178.
    View in: PubMed
    Score: 0.043
  130. Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016 07 08; 5(7).
    View in: PubMed
    Score: 0.043
  131. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke. 2016 08; 47(8):2075-82.
    View in: PubMed
    Score: 0.043
  132. The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. J Am Soc Echocardiogr. 2016 06; 29(6):537-44.
    View in: PubMed
    Score: 0.042
  133. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. Am Heart J. 2015 Oct; 170(4):669-74.
    View in: PubMed
    Score: 0.040
  134. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2015 Sep 01; 36(33):2239-45.
    View in: PubMed
    Score: 0.040
  135. The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade. J Interv Cardiol. 1995 Apr; 8(2):117-35.
    View in: PubMed
    Score: 0.039
  136. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 06; 385(9984):2280-7.
    View in: PubMed
    Score: 0.039
  137. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke. 2014 Aug; 45(8):2372-8.
    View in: PubMed
    Score: 0.037
  138. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). JACC Cardiovasc Interv. 2014 Jun; 7(6):604-12.
    View in: PubMed
    Score: 0.037
  139. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur Heart J. 2014 Jun 07; 35(22):1457-65.
    View in: PubMed
    Score: 0.036
  140. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28; 369(22):2093-104.
    View in: PubMed
    Score: 0.036
  141. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). J Am Coll Cardiol. 2014 Jan 28; 63(3):225-32.
    View in: PubMed
    Score: 0.036
  142. Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):555-9.
    View in: PubMed
    Score: 0.035
  143. Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. Clin Chem. 2014 Jan; 60(1):158-64.
    View in: PubMed
    Score: 0.035
  144. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation. 2012 Jan 31; 125(4):577-83.
    View in: PubMed
    Score: 0.031
  145. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol. 2012 Mar 22; 155(3):424-9.
    View in: PubMed
    Score: 0.029
  146. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010 Oct 16; 376(9749):1312-9.
    View in: PubMed
    Score: 0.029
  147. Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. JACC Cardiovasc Interv. 2010 Aug; 3(8):806-11.
    View in: PubMed
    Score: 0.028
  148. One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial. Eur Heart J. 2010 Sep; 31(17):2097-102.
    View in: PubMed
    Score: 0.028
  149. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.
    View in: PubMed
    Score: 0.027
  150. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation. 2010 Jan 05; 121(1):71-9.
    View in: PubMed
    Score: 0.027
  151. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am Heart J. 2009 Sep; 158(3):e21-6.
    View in: PubMed
    Score: 0.027
  152. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sep 19; 374(9694):989-997.
    View in: PubMed
    Score: 0.027
  153. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009 Aug 18; 54(8):678-85.
    View in: PubMed
    Score: 0.027
  154. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009 Aug; 49(8):984-98.
    View in: PubMed
    Score: 0.026
  155. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009 Jul; 30(14):1753-63.
    View in: PubMed
    Score: 0.026
  156. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009 May 19; 119(19):2553-60.
    View in: PubMed
    Score: 0.026
  157. Ventricular septal and free wall rupture complicating acute myocardial infarction: experience in the Multicenter Investigation of Limitation of Infarct Size. Am Heart J. 1989 Apr; 117(4):809-18.
    View in: PubMed
    Score: 0.026
  158. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009 Feb 28; 373(9665):723-31.
    View in: PubMed
    Score: 0.026
  159. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22; 360(4):354-62.
    View in: PubMed
    Score: 0.025
  160. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008 Oct 14; 118(16):1626-36.
    View in: PubMed
    Score: 0.025
  161. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008 Oct; 29(20):2473-9.
    View in: PubMed
    Score: 0.025
  162. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008 Apr 19; 371(9621):1353-63.
    View in: PubMed
    Score: 0.024
  163. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Am J Cardiol. 2008 May 01; 101(9):1367-70.
    View in: PubMed
    Score: 0.024
  164. The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2008 Dec 17; 131(1):105-12.
    View in: PubMed
    Score: 0.024
  165. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18; 116(25):2923-32.
    View in: PubMed
    Score: 0.024
  166. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Am Heart J. 2007 Dec; 154(6):1078-84, 1084.e1.
    View in: PubMed
    Score: 0.024
  167. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15; 357(20):2001-15.
    View in: PubMed
    Score: 0.024
  168. TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction. Am J Med. 2007 Nov; 120(11):993-8.
    View in: PubMed
    Score: 0.024
  169. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007 Jun 12; 49(23):2238-46.
    View in: PubMed
    Score: 0.023
  170. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. J Am Coll Cardiol. 2007 Jun 12; 49(23):2256-63.
    View in: PubMed
    Score: 0.023
  171. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006 Oct; 152(4):627-35.
    View in: PubMed
    Score: 0.022
  172. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich). 2006 May; 8(5):315-22.
    View in: PubMed
    Score: 0.021
  173. Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol. 2006 Apr 18; 47(8):1553-8.
    View in: PubMed
    Score: 0.021
  174. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation. 2005 Dec 20; 112(25):3846-54.
    View in: PubMed
    Score: 0.021
  175. Experimental and clinical observations on the efficacy of esmolol in myocardial ischemia. Am J Cardiol. 1985 Oct 23; 56(11):40F-48F.
    View in: PubMed
    Score: 0.020
  176. Use of an ultra short-acting beta-blocker in patients with acute myocardial ischemia. Circulation. 1985 Oct; 72(4):873-80.
    View in: PubMed
    Score: 0.020
  177. Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. Am Heart J. 2005 Jul; 150(1):79-88.
    View in: PubMed
    Score: 0.020
  178. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005 Jun 28; 111(25):3366-73.
    View in: PubMed
    Score: 0.020
  179. Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Am Heart J. 2005 May; 149(5):846-50.
    View in: PubMed
    Score: 0.020
  180. Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. Am J Cardiol. 2005 Feb 01; 95(3):337-42.
    View in: PubMed
    Score: 0.019
  181. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. J Am Coll Cardiol. 2005 Feb 01; 45(3):357-62.
    View in: PubMed
    Score: 0.019
  182. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jan 18; 45(2):321-3.
    View in: PubMed
    Score: 0.019
  183. Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. Am J Cardiol. 2005 Jan 15; 95(2):224-7.
    View in: PubMed
    Score: 0.019
  184. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Dec 01; 94(11):1406-10.
    View in: PubMed
    Score: 0.019
  185. Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Nov 01; 94(9):1113-7.
    View in: PubMed
    Score: 0.019
  186. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov; 25(22):1998-2005.
    View in: PubMed
    Score: 0.019
  187. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). Am J Cardiol. 2004 Sep 15; 94(6):774-6.
    View in: PubMed
    Score: 0.019
  188. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Sep 01; 44(5):980-7.
    View in: PubMed
    Score: 0.019
  189. Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries. Am J Cardiol. 2004 Jul 15; 94(2):178-81.
    View in: PubMed
    Score: 0.019
  190. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004 Jul 07; 292(1):89-96.
    View in: PubMed
    Score: 0.019
  191. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6.
    View in: PubMed
    Score: 0.018
  192. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003 Nov 05; 42(9):1535-43.
    View in: PubMed
    Score: 0.018
  193. Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction. Am J Cardiol. 2003 Oct 15; 92(8):913-8.
    View in: PubMed
    Score: 0.018
  194. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003 Jul 02; 42(1):7-16.
    View in: PubMed
    Score: 0.017
  195. Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial. Am Heart J. 2003 Jul; 146(1):42-7.
    View in: PubMed
    Score: 0.017
  196. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J. 2003 Jan; 145(1):109-17.
    View in: PubMed
    Score: 0.017
  197. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. Am Heart J. 2002 Oct; 144(4):649-56.
    View in: PubMed
    Score: 0.017
  198. The smoker's paradox: insights from the angiographic substudies of the TIMI trials. J Thromb Thrombolysis. 2002 Jun; 13(3):133-9.
    View in: PubMed
    Score: 0.016
  199. Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction. Eur Heart J. 2001 Nov; 22(22):2104-15.
    View in: PubMed
    Score: 0.016
  200. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol. 2001 Oct 15; 88(8):831-6.
    View in: PubMed
    Score: 0.015
  201. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J. 2001 Sep; 22(18):1702-15.
    View in: PubMed
    Score: 0.015
  202. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol. 2001 Aug 15; 88(4):353-8.
    View in: PubMed
    Score: 0.015
  203. Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. Am Heart J. 2001 Jul; 142(1):29-36.
    View in: PubMed
    Score: 0.015
  204. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001 May 29; 103(21):2550-4.
    View in: PubMed
    Score: 0.015
  205. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J. 2001 May; 141(5):742-50.
    View in: PubMed
    Score: 0.015
  206. Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. Catheter Cardiovasc Interv. 2001 May; 53(1):6-11.
    View in: PubMed
    Score: 0.015
  207. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. Am Heart J. 2001 Apr; 141(4):592-8.
    View in: PubMed
    Score: 0.015
  208. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. Am J Cardiol. 2001 Feb 15; 87(4):450-3, A6.
    View in: PubMed
    Score: 0.015
  209. Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction. Am J Cardiol. 2000 Dec 15; 86(12):1378-9, A5.
    View in: PubMed
    Score: 0.015
  210. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med. 1980 Dec; 93(6):886-904.
    View in: PubMed
    Score: 0.015
  211. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation. 2000 Jun 13; 101(23):2690-5.
    View in: PubMed
    Score: 0.014
  212. Differential effects of reperfusion on incidence of ventricular arrhythmias and recovery of ventricular function at 4 days following coronary occlusion. Am Heart J. 1987 May; 113(5):1055-65.
    View in: PubMed
    Score: 0.006
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.